NO20091182L - 2-fenoksypyrimidinonanaloger - Google Patents
2-fenoksypyrimidinonanalogerInfo
- Publication number
- NO20091182L NO20091182L NO20091182A NO20091182A NO20091182L NO 20091182 L NO20091182 L NO 20091182L NO 20091182 A NO20091182 A NO 20091182A NO 20091182 A NO20091182 A NO 20091182A NO 20091182 L NO20091182 L NO 20091182L
- Authority
- NO
- Norway
- Prior art keywords
- pets
- ligands
- compounds
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
Abstract
2-fenoksypyrimidinonanaloger er tilveiebrakt, med formelen: hvori variablene er som beskrevet heri. Slike forbindelser er ligander som kan anvendes for å modulere spesifikk reseptoraktivitet in vivo eller in vitro og er spesielt nyttige i behandlingen av tilstander forbundet med patologisk reseptoraktivering hos mennesker, kjæledyr og husdyr. Farmasøytiske sammensetninger og fremgangsmåter for anvendelse av slike forbindelser for behandling av slike lidelser er tilveiebrakt, det samme er fremgangsmåter for anvendelse av slike ligander for reseptorlokaliseringsstudier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82325806P | 2006-08-23 | 2006-08-23 | |
PCT/US2007/018654 WO2008024438A2 (en) | 2006-08-23 | 2007-08-22 | 2-phenoxy pyrimidinone analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091182L true NO20091182L (no) | 2009-05-14 |
Family
ID=39107411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091182A NO20091182L (no) | 2006-08-23 | 2009-03-20 | 2-fenoksypyrimidinonanaloger |
Country Status (22)
Country | Link |
---|---|
US (2) | US8003656B2 (no) |
EP (1) | EP2061794B1 (no) |
JP (1) | JP5421108B2 (no) |
KR (1) | KR20090043583A (no) |
CN (2) | CN101506210A (no) |
AU (1) | AU2007288203B2 (no) |
BR (1) | BRPI0716582A2 (no) |
CA (1) | CA2660957C (no) |
CO (1) | CO6150167A2 (no) |
CR (1) | CR10675A (no) |
EA (1) | EA200900330A1 (no) |
ES (1) | ES2399928T3 (no) |
GT (1) | GT200900040A (no) |
IL (1) | IL197043A0 (no) |
MA (1) | MA30720B1 (no) |
MX (1) | MX2009002066A (no) |
NI (1) | NI200900023A (no) |
NO (1) | NO20091182L (no) |
SV (1) | SV2009003173A (no) |
TW (1) | TW200825089A (no) |
WO (1) | WO2008024438A2 (no) |
ZA (1) | ZA200901163B (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
EA200900330A1 (ru) | 2006-08-23 | 2009-08-28 | Ньюроджен Корпорейшн | Аналоги 2-феноксипиримидинона |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN105530923B (zh) * | 2013-09-09 | 2019-07-23 | 佩洛通治疗公司 | 芳基醚及其用途 |
EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
EP3267792A4 (en) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
EP3908308A4 (en) * | 2019-01-08 | 2023-03-22 | Texas Tech University System | SMALL MOLECULES ANALOGS OF THE E4ORF1 PROTEIN IN THE TREATMENT AND PREVENTION OF METABOLIC DISORDERS |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008113A1 (fr) | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | COMPOSES DE 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE ET LEURS APPLICATIONS PHARMACOLOGIQUES |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
ATE227293T1 (de) | 1996-05-15 | 2002-11-15 | Pfizer | 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one |
US6432964B1 (en) | 1997-05-08 | 2002-08-13 | Agrevo Uk Limited | Fungicides |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
WO2002026718A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceutical, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
WO2002064598A1 (en) | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
CA2441599A1 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
JP2005504175A (ja) * | 2001-09-28 | 2005-02-10 | ダイムラークライスラー・アクチェンゲゼルシャフト | 高強度デュプレックス/トリプレックス軽量構造用鋼、及びその使用法 |
JP2005513154A (ja) | 2001-12-26 | 2005-05-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿素誘導体 |
JP2005526137A (ja) | 2002-05-17 | 2005-09-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノテトラリン−誘動尿素のバニロイドvr1受容体調節剤 |
WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
WO2004028440A2 (en) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
GB0326633D0 (en) | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
WO2005049613A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
WO2006122200A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
CN1318429C (zh) * | 2005-07-25 | 2007-05-30 | 华中师范大学 | 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶-4(3H)-酮及制备 |
US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
EA200900330A1 (ru) | 2006-08-23 | 2009-08-28 | Ньюроджен Корпорейшн | Аналоги 2-феноксипиримидинона |
AU2007288198A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
AU2007325940A1 (en) | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
WO2008156607A1 (en) | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Substituted pyrimidinones |
WO2009100403A1 (en) | 2008-02-07 | 2009-08-13 | Neurogen Corporation | Substituted aryl pyrimidinones |
WO2009121036A2 (en) | 2008-03-27 | 2009-10-01 | Neurogen Corporation | Substituted aryl pyrimidinone derivatives |
-
2007
- 2007-08-22 EA EA200900330A patent/EA200900330A1/ru unknown
- 2007-08-22 AU AU2007288203A patent/AU2007288203B2/en not_active Ceased
- 2007-08-22 ZA ZA200901163A patent/ZA200901163B/xx unknown
- 2007-08-22 CN CNA2007800309530A patent/CN101506210A/zh active Pending
- 2007-08-22 BR BRPI0716582-0A2A patent/BRPI0716582A2/pt not_active IP Right Cessation
- 2007-08-22 CA CA2660957A patent/CA2660957C/en not_active Expired - Fee Related
- 2007-08-22 MX MX2009002066A patent/MX2009002066A/es unknown
- 2007-08-22 KR KR1020097005810A patent/KR20090043583A/ko not_active Application Discontinuation
- 2007-08-22 JP JP2009525630A patent/JP5421108B2/ja not_active Expired - Fee Related
- 2007-08-22 ES ES07811503T patent/ES2399928T3/es active Active
- 2007-08-22 US US11/895,286 patent/US8003656B2/en active Active
- 2007-08-22 WO PCT/US2007/018654 patent/WO2008024438A2/en active Application Filing
- 2007-08-22 CN CN201410468406.2A patent/CN104292229A/zh active Pending
- 2007-08-22 TW TW096131019A patent/TW200825089A/zh unknown
- 2007-08-22 EP EP07811503A patent/EP2061794B1/en active Active
-
2009
- 2009-02-15 IL IL197043A patent/IL197043A0/en unknown
- 2009-02-20 NI NI200900023A patent/NI200900023A/es unknown
- 2009-02-20 SV SV2009003173A patent/SV2009003173A/es not_active Application Discontinuation
- 2009-02-23 GT GT200900040A patent/GT200900040A/es unknown
- 2009-03-18 CO CO09028167A patent/CO6150167A2/es unknown
- 2009-03-20 CR CR10675A patent/CR10675A/es not_active Application Discontinuation
- 2009-03-20 NO NO20091182A patent/NO20091182L/no not_active Application Discontinuation
- 2009-03-23 MA MA31732A patent/MA30720B1/fr unknown
-
2011
- 2011-08-22 US US13/215,195 patent/US8759361B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2008024438A2 (en) | 2008-02-28 |
KR20090043583A (ko) | 2009-05-06 |
CA2660957A1 (en) | 2008-02-28 |
ZA200901163B (en) | 2010-08-25 |
TW200825089A (en) | 2008-06-16 |
US20120208829A1 (en) | 2012-08-16 |
EP2061794A4 (en) | 2010-09-08 |
SV2009003173A (es) | 2010-08-10 |
AU2007288203B2 (en) | 2013-01-17 |
ES2399928T3 (es) | 2013-04-04 |
JP5421108B2 (ja) | 2014-02-19 |
NI200900023A (es) | 2010-03-05 |
MA30720B1 (fr) | 2009-09-01 |
CA2660957C (en) | 2016-10-11 |
CN104292229A (zh) | 2015-01-21 |
WO2008024438A3 (en) | 2008-11-27 |
EA200900330A1 (ru) | 2009-08-28 |
IL197043A0 (en) | 2009-11-18 |
CO6150167A2 (es) | 2010-04-20 |
MX2009002066A (es) | 2009-03-06 |
US20090069347A1 (en) | 2009-03-12 |
US8003656B2 (en) | 2011-08-23 |
GT200900040A (es) | 2010-03-16 |
CR10675A (es) | 2009-04-17 |
BRPI0716582A2 (pt) | 2013-10-08 |
CN101506210A (zh) | 2009-08-12 |
EP2061794A2 (en) | 2009-05-27 |
AU2007288203A1 (en) | 2008-02-28 |
US8759361B2 (en) | 2014-06-24 |
JP2010502576A (ja) | 2010-01-28 |
EP2061794B1 (en) | 2012-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092444L (no) | Heteroarylamidderivater | |
NO20091182L (no) | 2-fenoksypyrimidinonanaloger | |
NO20071243L (no) | Substituterte biarylpiperazinylpyridinanaloger. | |
MY148461A (en) | Heteroaryl amide analogues as p2x7 antagonists | |
WO2006078992A3 (en) | Heteroaryl substituted piperazinyl-pyridine analogues | |
NO20043411L (no) | Substituerte quinazolin-4-ylamin analoger | |
MY154668A (en) | 5-membered heterocyclic amides and related compounds | |
WO2006076646A3 (en) | Heteroaryl substituted quinolin-4-ylamine analogues | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
WO2006081388A3 (en) | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues | |
WO2007140383A3 (en) | Spirocyclic sulfonamides and related compounds | |
WO2006042289A3 (en) | Substituted biaryl quinolin-4-ylamine analogues | |
WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
WO2008024433A3 (en) | Haloalkyl-substituted pyrimidinone derivatives | |
WO2005084401A3 (en) | Aryl substituted purine analogues | |
WO2008066664A3 (en) | Cis-cyclohexyl substituted pyrimidinone derivatives | |
WO2008033739A3 (en) | Benzimidazole carboxamide derivatives | |
WO2005084368A3 (en) | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | |
WO2006071538A3 (en) | Substituted biaryl analogues | |
WO2005086968A3 (en) | Substituted 5,12-diaza-benzoanthracene analogues | |
WO2009121036A3 (en) | Substituted aryl pyrimidinone derivatives | |
WO2008002849A3 (en) | Aryl sulfones | |
DE602004007141D1 (de) | Aryl-substituierte benzoädüisothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |